Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in IgE-ACPA positive rheumatoid arthritis
NL-OMON37983Phase 2Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omalizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Leiden University Medical Center. Primary endpoints: Clinical disease activity by DAS44, Immunological parameters in peripheral blood and synovium and 4 more. Started Feb 2011; status: active, not recruiting.
02
Drugs
omalizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON37983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37983.